Standard-dose and short-term corticosteroid therapy in immunoglobulin- resistant Kawasaki disease

Clinical Pediatrics

Volumn 44, Issue 5, 2005, Pages 423-426

  Takeshita, Seiichiro ^a,b   Kawamura, Youichi ^b   Nakatani, Keigo ^b   Tsujimoto, Hiroshi ^b   Tokutomi, Tomoharu ^b  

^a UNIVERSITY OF SHIZUOKA   (Japan)

^b NATIONAL DEFENSE MEDICAL COLLEGE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; C REACTIVE PROTEIN; DOPAMINE; IMMUNOGLOBULIN; PREDNISOLONE; ULINASTATIN;

ARTHRITIS; ARTICLE; CHILD; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY DILATATION; CORTICOSTEROID THERAPY; DISEASE COURSE; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; INFANT; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; MYOCARDITIS; SHORT COURSE THERAPY; TREATMENT OUTCOME;

CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOGLOBULINS, INTRAVENOUS; INFANT; INFUSIONS, INTRAVENOUS; MALE; MUCOCUTANEOUS LYMPH NODE SYNDROME; PREDNISOLONE; PROSPECTIVE STUDIES; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 20944436504     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/000992280504400507     Document Type: Article

References (19)

1. Newburger JW, Takahashi M, Burns JC, et al. The treatment of Kawasaki syndrome with intravenous gamma globulin. N Engl J Med. 1986;315:341-347.
2. Newburger JW, Takahashi M, Beiser AS, et al. A single intravenous infusion of gamma globulin as compared with four infusions in the treatment of acute Kawasaki syndrome. N Engl J Med. 1991;324:1633-1639.
3. Hashino K, Ishii M, Iemura M, et al. Re-treatment for immune globulin-resistant Kawasaki disease: a comparative study of additional immune globulin and steroid pulse therapy. Pediatr Int. 2001;43:211-217.
4. Wright DA, Newburger JW, Baker A, Sundel RP. Treatment of immune globulin-resistant Kawasaki disease with pulsed doses of corticosteroids. J Pediatr. 1996;128:146-149.
5. Raman V, Kim J, Sharkey A, Chatila T. Response of refractory Kawasaki disease to pulse steroid and cyclosporin A therapy. Pediatr Infect Dis J. 2001;20:635-637.
6. Suzuki N, Seguchi M, Kouno C, et al. Rupture of coronary aneurysm in Kawasaki disease. Pediatr Int. 1999; 4:318-320.
7. Takahashi K, Oharaseki T, Wakayama M, et al. Pathological study of ruptured coronary artery aneurysms of Kawasaki disease (KD). Abstract from the 2nd World Congress of Pediatric Cardiology and Cardiac Surgery. 11-17 May 1997; p202.
8. Baethge BA, Lidsky MD, Goldberg JW. A study of adverse effects of high-dose intravenous (pulse) methylprednisolone therapy in patients with rheumatic disease. Ann Pharmacother. 1992;26:316-320.
9. Dale RC, Saleem MA, Daw S, Dillon MJ. Treatment of severe complicated Kawasaki disease with oral prednisolone and aspirin. J Pediatr. 2000;137:723-726.
10. Takagi N, Kihara M, Yamaguchi S, et al. Plasma exchange in Kawasaki disease. Lancet. 1995;346:1307.
11. Imagawa T, Miyamae T, Ito S, et al. Plasma exchange for intractable Kawasaki disease. Presented at 6th International Kawasaki Disease Symposium; 1999; Hawaii, USA.
12. Kato H, Koike S, Yokoyama T. Kawasaki disease: effect of treatment on coronary artery involvement. Pediatrics. 1979;63:175-179.
13. Newburger JW. Treatment of Kawasaki disease: corticosteroids revisited. J Pediatr. 1999;135:411-413.
14. Shinohara M, Sone K, Tomomasa T, Morikawa A. Corticosteroids in the treatment of the acute phase of Kawasaki disease. J Pediatr. 1999; 135:465-469.
15. Schwiebert LM, Beck LA, Stellato C, et al. Glucocorticosteroid inhibition of cytokine production: relevance to antiallergic actions. J Allergy Clin Immunol. 1996;97(1 Pt 2):143-152.
16. Leung DY, Cotran RS, Kurt-Jones E, et al. Endothelial cell activation and high interleukin-1 secretion in the pathogenesis of acute Kawasaki disease. Lancet. 1989;2:1298-1302.
17. Suzuki A, Miyagawa-Tomita S, Komatsu K, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. Circulation. 2000;101:2935-2941.
18. Nakano M. Evaluation of new urinastatin therapy for the acute phase of Kawasaki disease. Abstract from the 7th International Kawasaki disease symposium. 4-7, December 2001; P50.
19. Zaitsu M, Hamasaki Y, Tashiro K, et al. Ulinastatin, an elastase inhibitor, inhibits the increased mRNA expression of prostaglandin H2 synthase-type 2 in Kawasaki disease. J Infect Dis. 2000; 181:1101-1109.